Literature DB >> 597705

T1 bladder tumours.

J L Williams, J C Hammonds, N Saunders.   

Abstract

167 patients with T1 bladder transitional cell tumours treated by transurethral resection or cystodiathermy are reviewed. The overall crude survival was 83.2% in 3 years and 71.8% in 5 years. 7.8% of the patients developed an invasive tumour and these patients had an unfavourable initial tumour with moderate or poor differentiation and high or moderate mitotic rate. High or moderate pleomorphism was particularly unfavourable. Multiple tumours did as well as single ones but more of them had invasion of the lamina propria and a larger number were treated by either radiotherapy or cystectomy.

Entities:  

Mesh:

Year:  1977        PMID: 597705     DOI: 10.1111/j.1464-410x.1977.tb04549.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  4 in total

1.  Early adjuvant adriamycin in superficial bladder carcinoma.

Authors:  C C Schulman; L J Denis; W Oosterlinck; W De Sy; M Chantrie; C Bouffioux; P J Van Cangh; P Van Erps
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer.

Authors:  T Niijima; K Koiso; H Akaza
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

Authors:  D A Tolley; T B Hargreave; P H Smith; J L Williams; K M Grigor; M K Parmar; L S Freedman; B M Uscinska
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25

4.  Prognostic factors in WHO grade 2 transitional-cell bladder cancer (TCC); a novel two-grade classification system for TCC based on mitotic index.

Authors:  P K Lipponen; M J Eskelinen; K Jauhiainen; E Harju; P Terho; H Haapasalo
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.